FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

1. Name and Address of Reporting Person* Dake Benjamin T						2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)	ast) (First) (Middle) O AEROVATE THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 03/27/2024							X Officer (give title Other (specify below) SEE REMARKS					
930 WINTER STREET, SUITE M-500					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	AM M	ΙA	02451												filed by One filed by Mor on		•		
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - I	Non-Der	ivativ	e Sec	curit	ties Ac	quire	ed, D	isposed o	f, or Be	eneficial	ly Owne	d				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/You					Execution Date,				Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Transa	rted action(s) 3 and 4)			(Instr. 4)		
Common Stock 03/27/202					2024	:4		M ⁽¹⁾		11,068	A	\$10.61	1	2,359	D				
Common Stock 03/27/202				2024	24		S ⁽¹⁾		11,068	D	\$27.9652	(2)	,291	D					
		-	Table								posed of, , convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		e s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$10.61	03/27/2024			M ⁽¹⁾			11,068	(3)	12/13/2031	Common Stock	11,068	\$0	29,00	0	D		

Explanation of Responses:

- $1.\ This\ transaction\ was\ effected\ pursuant\ to\ a\ Rule\ 10b5-1\ trading\ plan\ adopted\ by\ the\ Reporting\ Person\ on\ November\ 16,\ 2023.$
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$27.95 to \$28.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 3. A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal

Remarks:

Officer Title: President, Chief Operating Officer and Secretary

/s/ George A. Eldridge, Attorney-in-Fact

** Signature of Reporting Person

03/28/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.